Skip to content
Triangle logo TriangleGet started
← Study library

NCT00416884 · REGISTRY CONDITION SEARCH

Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2017-09-27

RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total-body irradiation (TBI) before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) that have been treated in the laboratory after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and alemtuzumab, and removing the T lymphocyte cells(T cells) from the donor cells before transplant, may stop this from happening. PURPOSE: This clinical trial is studying how well giving fludarabine, alemtuzumab, and total-body irradiation together with donor stem cell transplant and donor white blood cell (WBC) infusion works in treating patients with chronic phase chronic myelogenous leukemia (CML) that did not respond to previous imatinib mesylate.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants With Treatment-related Mortality

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion criteria: * Patients aged 4-75 with chronic myelogenous leukemia (CML) treatable by allogeneic hematopoietic stem cell transplant. * Patients with cytogenetically confirmed chronic phase CML. o Hematologic parameters for chronic phase are: i) Percentage of blasts in peripheral blood or marrow \< 15% ii) Percentage of blasts + promyelocytes in the peripheral blood or bone marrow \< 30% iii) Percentage of basophils in blood or marrow \<20% iv) Platelet count \> 100 x 109/l * Patients must have demonstrated refractoriness/resistance to STI571 defined as follows: i) Hematologically resistant- failure to achieve a complete hematologic remission (CHR) despite 3 months of STI571 therapy. ii) Hematologically refractory - a rising WBC count \> 20 x 109/l confirmed by two samples taken two weeks apart in a patient with a previous CHR despite concurrent treatment with STI571 iii) Cytogenetically resistant - bone marrow cytogenetics showing \> 65% Philadelphia chromosome positivity (Ph+) after 6 months of STI571 based therapy. iv) Cytogenetically refractory - An increase in the number of Philadelphia chromosome positive (Ph+) bone marrow cells by at least 30%, or an increase to \> 65%, confirmed by samples at least 1 month apart following a previous STI571 induced cytogenetic response, while continuing STI571 therapy. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Patients with a human leukocyte antigen (HLA) matched sibling donor at the HLA-A, B, and DR loci. * Patients with an unrelated hematopoietic stem cell donor must be matched using high resolution typing for class II human leukocyte antigen (HLA-DR beta-1, 3, 4, 5 and DQ beta-1) and matched with intermediate to high resolution molecular typing at class I human leukocyte antigen (HLA-A, B, and C) loci. * Patients with accelerated or blast crisis of CML who have returned to chronic phase as described above are eligible. * Written informed, voluntary consent. Exclusion criteria: * Patients who have received another investigational drug within 30 days. * Fertile men unwilling to use contraceptive techniques during and for 24 months following treatment. * Females who are pregnant or fertile women unwilling to use contraceptive techniques for two months prior to entering the study and for 24 months following treatment. * Patients with active bacterial or fungal infections unresponsive to medical therapy. * Patients with organ dysfunction including cardiac ejection fraction of less than 35% or pulmonary status with a diffusing capacity of the lung for carbon monoxide(DLCO) of less than 40% and/or receiving supplemental oxygen. * Liver Function Abnormalities: patients will be excluded if they are found to have fulminant liver failure, cirrhosis of the liver with evidence of portal hypertension, alcoholic hepatitis, varices, history of bleeding varices, hepatic encephalopathy or chronic viral hepatitis where the total serum bilirubin is greater than 3 mg per deciliter with symptomatic biliary disease. * Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable. * Patients with a history of any prior bone marrow or peripheral blood stem cell transplantation. * Patients with any other serious, uncontrolled, concomitant medical condition * HIV positive patients Eligibility criteria for donors: Inclusion Criteria for Donors: * Sibling donors are permitted if matched at class I human leukocyte antigen (HLA-A, B), and class II human leukocyte antigen (DR) loci. * Unrelated donors must be matched for class II human leukocyte antigen(HLA-DR beta-1,2,3,4,5) and class II human leukocyte antigen (DQ beta-1) with high resolution typing and with intermediate resolution molecular typing at class I human leukocyte antigen(HLA-A, B, and C) loci. * Donors must be eligible to serve as a peripheral stem cell allograft donor. Bone marrow donors will not be permitted on this protocol. * Donors must be \>18 and \< 75 years of age. Exclusions Criteria for Donors: * Volunteer donors who wish to serve as bone marrow donors only and refuse exogenous cytokines. * Donors who are Human immunodeficiency virus (HIV+), Human T-lymphotropic virus (HTLV-1+), or hepatitis Bs Ag+.. * Donors with medical conditions that would result in increased risk for Granulocyte colony-stimulating factor (G-CSF) mobilization and harvest of peripheral blood stem cells (PBSC) including renal insufficiency with Cr \> 2.0, idiopathic splenomegaly, underlying coagulopathy, uncontrolled coronary artery disease, and major surgery within 28 days.
healthy Volunteers
false
maximum Age
75 Years
minimum Age
4 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
  3. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    (Campath) 30 mg on day -8 over 5-6 hours, Fludarabine 30 mg/m\^2 on day -4 through day -2, Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0., Stem cells will be T cell depleted and given on day 0
    intervention Names
    1. Drug: Campath
    2. Drug: Fludarabine
    3. Radiation: Total Body Irradiation (TBI)
    4. Other: T-Cell Deplete
    label
    TBI, Campath, Fludarabine T-cell Deplete
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. TBI, Campath, Fludarabine T-cell Deplete
    description
    30 mg on day -8 over 5-6 hours
    name
    Campath
    other Names
    1. Nonmeylablative Stem Cell Transplant
    2. Mini Transplant
    type
    DRUG
  2. arm Group Labels
    1. TBI, Campath, Fludarabine T-cell Deplete
    description
    Fludarabine 30 mg/m\^2 on day -4 through day -2
    name
    Fludarabine
    other Names
    1. Nonmeylablative Stem Cell Transplant
    2. Mini Transplant
    type
    DRUG
  3. arm Group Labels
    1. TBI, Campath, Fludarabine T-cell Deplete
    description
    Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
    name
    Total Body Irradiation (TBI)
    other Names
    1. Nonmeylablative Stem Cell Transplant
    2. Mini Transplant
    type
    RADIATION
  4. arm Group Labels
    1. TBI, Campath, Fludarabine T-cell Deplete
    description
    Stem cells will be T cell depleted and given on day 0
    name
    T-Cell Deplete
    other Names
    1. Nonmeylablative Stem Cell Transplant
    2. Mini Transplant
    type
    OTHER
Study design
allocation
NON_RANDOMIZED
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
1
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Treatment related mortality is a consequence of both complications of the preparative regimen and systemic immunological rejection which is manifested as graft versus host disease(GVHD). The preparative regimens which include whole body radiation and/or high dose chemotherapy are complicated by single or multi-organ failure and by prolonged myelosuppression that can lead to infections and bleeding
    measure
    Number of Participants With Treatment-related Mortality
    time Frame
    lifetime followup, up to 100 years.
Full study description
brief Summary
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and total-body irradiation (TBI) before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) that have been treated in the laboratory after the transplant may help increase this effect. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and alemtuzumab, and removing the T lymphocyte cells(T cells) from the donor cells before transplant, may stop this from happening. PURPOSE: This clinical trial is studying how well giving fludarabine, alemtuzumab, and total-body irradiation together with donor stem cell transplant and donor white blood cell (WBC) infusion works in treating patients with chronic phase chronic myelogenous leukemia (CML) that did not respond to previous imatinib mesylate.
detailed Description
OBJECTIVES: * Determine the treatment-related mortality in patients with imatinib mesylate-resistant chronic phase chronic myelogenous leukemia treated with nonmyeloablative conditioning comprising fludarabine, alemtuzumab, and total-body irradiation followed by T-cell-depleted allogeneic stem cell transplantation and post-transplantation allogeneic T-cell infusion. * Determine if donor engraftment can be safely established using partial T-cell depletion with additional T-cell infusions in these patients. OUTLINE: Patients receive alemtuzumab IV over 5-6 hours on day -8 and fludarabine IV on days -4 to -2. Patients undergo total-body irradiation followed by T-cell-depleted (CD34+ selected) allogeneic stem cell transplantation on day 0. Patients receive allogeneic T-cell infusion on days 30 and 60. Patients also receive cyclosporine twice daily beginning on day -3 and continuing until day 100 followed by a taper until day 177. PROJECTED ACCRUAL: Not specified.
Source references
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-18ed866827049d931492
      requested nct id
      NCT00416884
      primary nct id
      NCT00416884
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      payload sha256
      2349be1b786ed0840a5fa2a6efc831882c0f4eb4679131d107d428a38a168a36
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-18ed866827049d931492
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00416884
      occurrences
      1. context exact
        NCT00416884
        end
        11
        exact text
        NCT00416884
        start
        0
      offset unit
      unicode_code_points
      query cond
      Childhood Chronic Myeloid Leukemia
      query disease state id
      ds-chronic-myeloid-leukemia-pediatric
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-childhood-chronic-myeloid-leukemia-000.json
      source file sha256
      193739e64f77123de4344901c9970a0996a667fa587f14135380bef3ae38e11d
      source json pointer
      /studies/38/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      ec235b4acef03eb5421e8cef8552655549e14b6ca49736c8cc5305013e12de96

    Preserved source evidence · Not medical advice